Friday, August 8, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Advancing Chronic Kidney Disease Management through Genetic Testing Natera Endorses 2024 KDIGO Clinical Practice Guideline

Elaine Mendonca by Elaine Mendonca
March 14, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Natera, a leading company specializing in cell-free DNA testing, has announced its endorsement of the 2024 Clinical Practice Guideline established by the Kidney Disease Improving Global Outcomes (KDIGO) organization. This guideline promotes the use of genetic testing to identify the root cause of chronic kidney disease (CKD) in the majority of patients, emphasizing the significance of genetic testing in determining the cause of CKD and its impact on clinical management.

The KDIGO guideline specifically outlines various scenarios where genetic testing can provide valuable insights for CKD patients, such as in cases with a high prevalence of monogenic subtypes, early onset of CKD, syndromic features, consanguinity, potential targeted treatments, and instances where kidney biopsy does not yield informative results.

Natera’s RenasightTM test is in alignment with this guideline, offering comprehensive genetic testing for kidney disease. This test screens for hereditary causes of kidney disease, providing essential information for disease management, predicting disease progression, and guiding treatment decisions. With over 380 genes analyzed by genetic experts, the Renasight test offers actionable insights and can be accessed through remote testing services with rapid results turnaround.

A recent study conducted by Natera, known as RenaCARE, showcased the diagnostic and clinical benefits of Renasight in CKD patients. The study revealed that genetic testing with Renasight resulted in new or reclassified diagnoses for half of positive patients, influencing treatment plans for one-third of positive patients. These findings underscore the importance and advantages of genetic testing in effectively managing chronic kidney disease.

NTRA Stock Shows Mixed Performance on March 14, 2024: What to Expect Next

On March 14, 2024, NTRA stock showed some mixed performance as it traded near the top of its 52-week range and above its 200-day simple moving average. Despite these positive indicators, the stock experienced a slight decrease in price, falling $1.20 since the market last closed, representing a 1.35% drop.

Investors may be keeping a close eye on NTRA stock to see if this downward trend continues or if the stock rebounds in the coming days. The fact that the stock is still trading near the top of its 52-week range and above its 200-day moving average suggests that there may still be some positive momentum for NTRA in the long term.

NTRA Stock Shows Positive Performance with 31.99% Increase in Revenue

On March 14, 2024, NTRA stock showed positive performance based on its financial results. According to data from CNN Money, NTRA reported a total revenue of $1.08 billion for the past year, which represents a 31.99% increase compared to the previous year. In the fourth quarter alone, the company generated $311.11 million in total revenue, showing a 15.95% increase from the previous quarter.

In terms of net income, NTRA reported a loss of $434.80 million for the past year, but this figure actually represents a 20.63% improvement compared to the previous year. In the fourth quarter, the company’s net loss was $78.03 million, showing a significant 28.43% increase from the previous quarter.

Earnings per share (EPS) for NTRA also showed positive growth trends. The company reported an EPS of -$3.78 for the past year, which is a 32.08% improvement compared to the previous year. In the fourth quarter, the EPS was -$0.65, which remained flat compared to the previous quarter.

Tags: NTRA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Trading online

Ascendis Pharma A Remarkable Investment Success Story

Healthcare-and-IT

Grifols Focuses on Deleveraging Strategy for Enhanced Financial Performance

Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Anticipating Hibbetts Earnings Report What Investors Need to Know

Recommended

ALB stock news

Allspring Global Investments Increases Stake in Automotive Parts Company, Douglas Dynamics Inc.

2 years ago
Technology Robotics Markets and money

Exela Technologies Inc and XBP Europe Launch Reaktrai Revolutionizing Cybersecurity and Data Management with AI

2 years ago

Positive Outlook and Increased Price Target for Corteva

2 years ago
Alternative Energy Markets and money (1)

Ecopetrols Commitment to Thorough Evaluation and Reliable Results for Arauca 8 Well

2 years ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN AVGO BA C CCL CELH COIN COST CRWD CTVA DELL DFS DIS DLR DLTR DWAC GM GRFS IBM INTC JPM KSS LLY META MSFT NFLX NVDA NVO ORCL PARA PLTR PLUG QCOM SMCI TGT TSLA UNH VZ
No Result
View All Result

Highlights

Lucid Group Stock: Turbulence Amid Policy Shifts and Uber Deal

Walt Disney Stock: Marvel Woes Offset by NFL Deal

Fresenius Stock: Mixed Q2 Results Amid Margin Pressures

Beiersdorf Stock: Nivea’s Glow Fades as Forecasts Dim

ABN Amro Stock: Profit Dip Amid Strong Capital Moves

Vonovia Stock: Strong Recovery Fuels Optimism

Trending

Snap Stock
Stocks

Snap Stock: Turmoil Amid Advertising Woes

by Dieter Jaworski
August 6, 2025
0

Snap Inc.'s stock has become a battleground for Wall Street analysts following disappointing Q2 results, with price...

DHL Stock

DHL Stock: Rollercoaster Ride Amid Strong Earnings

August 6, 2025
Klöckner Stock

Klöckner Stock: Turnaround Amid Market Volatility

August 6, 2025
Lucid Group Stock

Lucid Group Stock: Turbulence Amid Policy Shifts and Uber Deal

August 6, 2025
Walt Disney Stock

Walt Disney Stock: Marvel Woes Offset by NFL Deal

August 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Desert Gold Ventures Stock: Mali Gold Project Sparks Investor Optimism August 8, 2025
  • Sony Stock: Defies Tariff Fears with Stellar Earnings August 8, 2025
  • Motorola Stock: Strong Earnings Beat Lifts Outlook August 8, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com